Pfizer to Buy King Pharmaceuticals for $14.25 a Share

Drug maker Pfizer Inc. (PFE) today announced that it has agreed to pay $3.6 billion, or $14.25 a share, in cash to buy King Pharmaceuticals Inc (KG). The proposed acquisition represents a 40% premium to King’s closing share price as of October 11, 2010.

The deal, which is approved by the boards of both co.’s, is Pfizer’s largest since it bought rival Wyeth for $68 billion in 2009.

Pfizer said the purchase will add about $0.02 per share to its net income in 2011 and 2012, and approximately $0.03 – $0.04 annually from 2013 through 2015.

King shares rose 39.41% –the most intraday since November 1999. — early Tuesday to $14.15 while Pfizer was off 2 cents at $17.36.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.